The scale of the problem is difficult to overstate. Earlier literature-based analyses cited in the perspective estimate that nearly one billion people worldwide suffer from obstructive sleep apnea, the majority of them undiagnosed. Obesity, meanwhile, has been firmly established by epidemiological studies as a risk factor for at least a dozen malignancies, and recent Mendelian randomization work linking adiposity distribution to obesity-related cancers has strengthened the case that the association is causal rather than merely correlational. What the new perspective adds is a synthesis of mechanistic and clinical evidence suggesting that sleep apnea is not simply a byproduct of obesity but an independent contributor to cancer risk, one that operates through distinct biological channels that persist even after body weight is taken into account.

At the heart of the apnea-cancer connection lies intermittent hypoxia, the repeated cycles of oxygen desaturation and reoxygenation that occur when the upper airway collapses during sleep. Far from being a benign inconvenience, this oscillation resembles ischemia-reperfusion injury in miniature, occurring hundreds of times each night. Each cycle generates bursts of reactive oxygen species, activates inflammatory signaling cascades, and imposes oxidative stress on tissues throughout the body. Experimental work in mouse models has shown that intermittent hypoxia can accelerate tumor growth, and that the effect is amplified when hypoxia is combined with obesity, suggesting the two exposures act synergistically rather than additively on the tumor microenvironment.

The perspective highlights several mechanistic frontiers that have matured considerably in recent years. Among the most striking is the role of immune checkpoint signaling. Research summarized by the authors demonstrates that intermittent hypoxia and sleep fragmentation upregulate PD-1 and PD-L1, the very molecular brakes that many modern cancer therapies are designed to block. In effect, sleep apnea may mimic one of the central evasion strategies that tumors use to escape immune surveillance. Further studies have identified additional checkpoints, including PSGL-1 and the galectin-9/TIM-3 axis, as markers of T-cell dysfunction in apnea patients, and circulating small extracellular vesicles carrying PD-L1 have been detected in affected individuals. Dysregulation of the CD39/CD73 adenosine pathway, another immunosuppressive circuit, adds yet another layer to this immune sabotage.

Beyond immunity, the perspective draws attention to extracellular matrix remodeling and metabolic-hepatic pathways as key mediators of apnea-related oncogenesis. Adipose tissue itself is far from inert: in obesity, fat depots become poorly oxygenated, infiltrated by macrophages, and chronically inflamed, a state that experimental studies show is worsened by intermittent hypoxia. Macrophage polarization within fat tissue, driven by hypoxic cycles, can reshape the tumor microenvironment in ways that favor malignancy. In the liver, chronic intermittent hypoxia has been shown to increase cell proliferation in hepatocellular carcinoma models, and hypoxia has been found to differentially modulate the release of mitochondrial and nuclear DNA, fragments of which can circulate as inflammatory triggers. Exosomes, the tiny vesicles cells use to ship molecular cargo, appear to carry pro-malignant signals from apnea patients: plasma exosomes from people with obesity hypoventilation syndrome have been shown to drive malignant properties in lung cancer cells, and long-term continuous positive airway pressure treatment appears to blunt this effect.

Epidemiologically, the evidence linking sleep apnea to cancer has grown steadily more convincing, though the authors are careful to acknowledge that residual confounding remains a persistent challenge. Systematic reviews and meta-analyses have associated obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality. Large cohort studies have reported that self-reported witnessed apneas are associated with incident lung and breast cancer, that episodic hypoxemia accelerates lung cancer recurrence and mortality, and that sex-specific associations exist between sleep apnea and lung cancer risk in patients with COPD. A prospective multicenter study of 443 melanoma patients found that sleep apnea was related to melanoma aggressiveness, and that long-term CPAP treatment influenced prognosis. Mendelian randomization analyses, which use genetic variants to probe causality, have begun to support causal associations between sleep apnea and cancer risk, lending additional weight to the observational findings.

Perhaps the most consequential shift in the field concerns how sleep apnea severity is measured. For decades, the apnea-hypopnea index, a simple count of breathing interruptions per hour, has been the gold standard metric. The perspective argues that this index is increasingly obsolete as a predictor of cancer-related outcomes. Newer metrics, particularly hypoxic burden, a quantitative measure of the total oxygen desaturation a patient experiences during sleep, and nocturnal oxygen desaturation indices, outperform the apnea-hypopnea index in predicting adverse health outcomes, including cardiovascular morbidity and mortality. This reframing matters because two patients with identical apnea-hypopnea index values can carry vastly different hypoxic loads, and it is the hypoxemia, rather than the snoring itself, that appears to drive downstream pathology. Multi-trial analyses have similarly shown that the cardiovascular benefit of CPAP is concentrated in patients with high-risk profiles defined by such physiological burdens.

On the therapeutic front, the perspective outlines a rapidly evolving landscape. Continuous positive airway pressure, the standard treatment for sleep apnea, may mitigate hypoxemia-related pathways, and studies of exosome biology suggest that long-term adherence can reduce the pro-malignant signaling carried in patients’ plasma. More dramatically, the arrival of GLP-1 and GIP receptor agonists has created an unprecedented opportunity to attack the triad at its metabolic root. The tirzepatide trials demonstrated efficacy for both obesity and obstructive sleep apnea, and a growing body of pharmacoepidemiological evidence, including nationwide cohort studies and target trial emulations, links GLP-1 receptor agonists to reduced risks of overall cancer, colorectal cancer, and obesity-related cancers in adults with obesity or type 2 diabetes. Bariatric surgery, meanwhile, has been associated in nationwide matched cohort studies with reduced cancer risk compared with the general population, including a specifically documented reduction in hematological malignancies in a large French administrative data study.

None of this means that a CPAP mask or an injection is a cancer vaccine, and the authors are explicit about the limits of the current evidence. Observational studies cannot fully exclude confounding by obesity, smoking, alcohol use, and socioeconomic factors, and the mechanistic work, while compelling, derives largely from cell cultures and animal models whose translation to human tumors is incomplete. Intentional weight loss has been associated with reduced cancer incidence in systematic reviews, but disentangling the contribution of improved breathing from that of reduced adiposity itself will require carefully designed interventional trials. The perspective also notes that obesity metrics themselves are being rethought, with body shape indices and frameworks that move beyond body mass index offering finer resolution of which patients carry the greatest cancer risk.

What emerges from the synthesis is a call for precision medicine approaches that integrate hypoxemia phenotyping, immune profiling, and targeted interventions to optimize both prevention and treatment. In practical terms, this could mean that a patient’s nocturnal oxygen profile becomes part of oncological risk stratification, that immune checkpoint biomarkers measured in sleep apnea patients help predict melanoma or lung cancer mortality, or that incretin-based therapies are deployed not merely for weight loss but as dual-purpose agents that simultaneously shrink apnea severity and cancer risk. The perspective, funded in part by Spain’s Instituto de Salud Carlos III, reframes three of the most common conditions of modern life as a single, intertwined biological problem. If the mechanistic and epidemiological threads it weaves together continue to hold, the humble snore may prove to be one of the most underappreciated cancer risk factors of our time, and treating it thoroughly, rather than tolerating it, could become a genuine pillar of cancer prevention.

Subject of Research: The interplay between obesity, obstructive sleep apnea, and cancer risk and progression

Article Title: Obesity, sleep apnea and cancer revisited

Article References: Sánchez-de-la-Torre, M., & Gozal, D. (2026). Obesity, sleep apnea and cancer revisited. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02230-z

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02230-z

Keywords: obesity, obstructive sleep apnea, cancer, intermittent hypoxia, hypoxic burden, immune checkpoint, PD-L1, CPAP, GLP-1 receptor agonists, bariatric surgery, inflammation, tumor microenvironment